First Berlin Releases Research Update Following Callisto Pharmaceutical's Announcement Of Initiation Of Phase II Trial In Advanced Carcinoid Cancer
15th Nov 2006, 12:32 GMT
Callisto Pharmaceuticals, Inc. KAL (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced that a leading independent research firm, First Berlin Equity Research, has issued an updated research report with a "Buy" rating, and a speculative risk rating. [click link for full article]
First Berlin Releases Research Update Following Callisto Pharmaceutical's Announcement Of Initiation Of Phase II Trial In Advanced Carcinoid Cancer related news:
- 1st Berlin Releases Research Update Following Callisto Pharmaceutical's Announcement of Initiation of Phase II Trial in Advanced Carcinoid Cancer Patients — Pharmaceuticals News from StratCenter.com
- CuraGen and TopoTarget Announce Initiation of NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer — PR Newswire: All Releases
- CuraGen, TopoTarget initiate ovarian cancer trial — Pharmaceutical Business Review Latest News
- Reata brain cancer therapy shows strong activity — Pharmaceutical Business Review Latest News
- Aeterna prostate cancer drug shows promise — Pharmaceutical Business Review Latest News
- Systemic Treatment Before Surgery For Kidney Cancer Prolongs Patients' Survival — Health News from Medical News Today
- Enzyme Inhibitor Produces Stable Disease In Patients With Advanced Solid Cell Cancers: Phase II Trials Initiated — Health News from Medical News Today
- ART Advanced Research Technologies Announces 2006 Third Quarter Financial Results — ArriveNet : Health
- Scientists Design A PSA-activated Protoxin That Kills Prostate Cancer: Phase I Clinical Trial Is Under Way — Health News from Medical News Today
- Human Genome reports positive results on lupus drug — Pharmaceutical Business Review Latest News
Latest news from Health News from Medical News Today:
- Biotech Industry Welcomes WHO Initiative On Naming Of Biologicals Including Biosimilar Medicines
- Common Cause Of Heart Disease, Diabetes May Be Treatable With Malaria Drug
- Two Nerve Cells In Direct Contact
- Value Of 'Helper' Compound In Treating Some Leukemias
- Internists Take Home Several National Awards At AAMC Annual Meeting
- Most Canadian Med School Grads Lack Basic Surgical Skills
- ACP's Electronic Medical Resource Ranked No. 1 Evidence-based Tool By MLA's South Central Chapter
- University Of Illinois Scientist Helping Processors Keep E. Coli Out Of Meat
- American Thoracic Society Publishes New Statement On Hepatotoxicity Of Antituberculosis Therapy
- Neural Networking Nanotubes